JP2017534645A5 - - Google Patents

Download PDF

Info

Publication number
JP2017534645A5
JP2017534645A5 JP2017525016A JP2017525016A JP2017534645A5 JP 2017534645 A5 JP2017534645 A5 JP 2017534645A5 JP 2017525016 A JP2017525016 A JP 2017525016A JP 2017525016 A JP2017525016 A JP 2017525016A JP 2017534645 A5 JP2017534645 A5 JP 2017534645A5
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
acid sequence
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017525016A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017534645A (ja
JP6946184B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/075877 external-priority patent/WO2016075036A1/en
Publication of JP2017534645A publication Critical patent/JP2017534645A/ja
Publication of JP2017534645A5 publication Critical patent/JP2017534645A5/ja
Application granted granted Critical
Publication of JP6946184B2 publication Critical patent/JP6946184B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017525016A 2014-11-10 2015-11-06 抗pdgf−b抗体及び使用法 Expired - Fee Related JP6946184B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14192519.8 2014-11-10
EP14192519 2014-11-10
PCT/EP2015/075877 WO2016075036A1 (en) 2014-11-10 2015-11-06 Anti-pdgf-b antibodies and methods of use

Publications (3)

Publication Number Publication Date
JP2017534645A JP2017534645A (ja) 2017-11-24
JP2017534645A5 true JP2017534645A5 (OSRAM) 2018-12-06
JP6946184B2 JP6946184B2 (ja) 2021-10-06

Family

ID=51947140

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017525016A Expired - Fee Related JP6946184B2 (ja) 2014-11-10 2015-11-06 抗pdgf−b抗体及び使用法

Country Status (15)

Country Link
US (1) US10087246B2 (OSRAM)
EP (1) EP3218400A1 (OSRAM)
JP (1) JP6946184B2 (OSRAM)
KR (1) KR20170082520A (OSRAM)
CN (1) CN107148429B (OSRAM)
AR (1) AR102593A1 (OSRAM)
AU (1) AU2015345322A1 (OSRAM)
BR (1) BR112017009792A2 (OSRAM)
CA (1) CA2963723A1 (OSRAM)
IL (1) IL251286A0 (OSRAM)
MX (1) MX2017005975A (OSRAM)
RU (1) RU2017120361A (OSRAM)
SG (1) SG11201703426PA (OSRAM)
TW (1) TW201630934A (OSRAM)
WO (1) WO2016075036A1 (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2537100T3 (es) 2009-04-07 2015-06-02 Roche Glycart Ag Anticuerpos biespecíficos trivalentes
RU2017120360A (ru) 2014-11-10 2018-12-13 Ф.Хоффманн-Ля Рош Аг Биспецифические антитела и способы их применения в офтальмологии
JP2017534644A (ja) 2014-11-10 2017-11-24 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 抗ang2抗体及び使用方法
AU2015345320A1 (en) 2014-11-10 2017-04-06 F. Hoffmann-La Roche Ag Anti-IL-1beta antibodies and methods of use
JP6721590B2 (ja) 2014-12-03 2020-07-15 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 多重特異性抗体
WO2017020001A2 (en) * 2015-07-29 2017-02-02 Allergan, Inc. Heavy chain only antibodies to ang-2
WO2020219774A1 (en) * 2019-04-24 2020-10-29 Magenta Therapeutics, Inc. Anthracycline antibody-drug conjugates and uses thereof
EP4126940A1 (en) 2020-03-30 2023-02-08 F. Hoffmann-La Roche AG Antibody that binds to vegf and pdgf-b and methods of use
CN116964088A (zh) * 2021-01-25 2023-10-27 里珍纳龙药品有限公司 用于治疗肺动脉高压(pah)的抗pdgf-b抗体和使用方法
WO2025150482A1 (en) * 2024-01-08 2025-07-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules that bind pdgf-b and pdgf-d, and methods of use
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935343A (en) 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
CN1780855B (zh) 2003-01-24 2011-03-30 应用分子进化公司 人IL-1β拮抗剂
NZ601544A (en) * 2003-08-27 2013-11-29 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
WO2005087812A1 (en) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
DE102004062361A1 (de) * 2004-12-10 2006-06-22 Cocreate Software Gmbh & Co. Kg Verfahren zur Ableitung von technischen Zeichungen aus 3D Modellen mit mindestens zwei kollidierenden 3D Körpern
JP4884395B2 (ja) * 2004-12-21 2012-02-29 アストラゼネカ エービー アンジオポエチン−2に対する抗体およびそれらの使用
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗-vegf/抗-ang-2抗體
WO2014001442A1 (en) 2012-06-28 2014-01-03 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
UA120029C2 (uk) * 2012-07-13 2019-09-25 Рош Глікарт Аг Спосіб зниження в'язкості біспецифічного антитіла до vegf/ang-2 та застосування такого антитіла для лікування судинних очних захворювань
EP3721872B1 (en) * 2012-11-08 2025-01-22 Clearside Biomedical Inc. Methods for the treatment of ocular disease in human subjects
CA2890483A1 (en) * 2012-11-09 2014-05-15 Robert ARCH Platelet-derived growth factor b specific antibodies and compositions and uses thereof
JO3405B1 (ar) * 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
ES2746136T3 (es) 2013-04-29 2020-03-04 Hoffmann La Roche Anticuerpos modificados de unión a FcRn humano y procedimientos de uso
CN105899534B (zh) 2014-01-15 2020-01-07 豪夫迈·罗氏有限公司 具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体
JP2017534644A (ja) 2014-11-10 2017-11-24 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 抗ang2抗体及び使用方法
AU2015345320A1 (en) 2014-11-10 2017-04-06 F. Hoffmann-La Roche Ag Anti-IL-1beta antibodies and methods of use
RU2017120360A (ru) 2014-11-10 2018-12-13 Ф.Хоффманн-Ля Рош Аг Биспецифические антитела и способы их применения в офтальмологии

Similar Documents

Publication Publication Date Title
JP2017534645A5 (OSRAM)
JP2017534646A5 (OSRAM)
JP2020062036A5 (OSRAM)
JP2017534644A5 (OSRAM)
JP2017537896A5 (OSRAM)
RU2017120360A (ru) Биспецифические антитела и способы их применения в офтальмологии
JP2019501883A5 (OSRAM)
HRP20211528T1 (hr) Trispecifični i/ili trovalentni vezujući proteini za prevenciju ili liječenje hiv infekcije
RU2017120358A (ru) Анти-il-1-бета антитела и способы их применения
HRP20191584T1 (hr) Anti-cd79b protutijela i načini uporabe
RU2019134352A (ru) Новые биспецифические антигенсвязывающие молекулы, обладающие способностью специфически связываться с cd40 и fap
RU2017120361A (ru) Антитела к pdgf-b и способы их применения
JP2020500538A5 (OSRAM)
JP2018537966A5 (OSRAM)
JP2014511179A5 (OSRAM)
JP2016512551A5 (OSRAM)
JP2019536806A5 (OSRAM)
HRP20200384T1 (hr) Humanizirana anti-tau(ps422) protutijela i načini uporabe
RU2020124153A (ru) Гуманизированные антитела к cd19 человека и способы их применения
JP2017504566A5 (OSRAM)
JP2011046732A5 (OSRAM)
JP2017528476A5 (OSRAM)
JP2015533795A5 (OSRAM)
HRP20211641T1 (hr) Bispecifična protutijela anti-vegf/anti-ang-2 i njihova primjena u liječenju vaskularnih očnih bolesti
JP2018521638A5 (OSRAM)